A Japanese Company Initiates Development of a Plasma-Derived Therapy for COVID-19

Sunday, March 8, 2020 - 13:01

Takeda Pharmaceutical Company has started to develop an anti-SARS-CoV-2 polyclonal hyperimmune globin, a plasma-derived drug, which will harness the blood of coronavirus patients who have recovered from their infections.

According to the company's official website, Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19.

By using this method, researchers hope to harness the antibodies produced by previous patients as a successful treatment for new patients, with the aim of strengthening their immune systems and reducing the severity of symptoms associated with the novel virus.

As well as its research into a plasma-derived drug, which the company has named TAK-888, Takeda will study its marketed and pipeline products to see if they could be effective for the treatment of the novel coronavirus.

“We have identified relevant assets and capabilities across the company and are hopeful that we can expand the treatment options for patients with COVID-19 and the providers caring for them,” said Rajeev Venkayya, president of Takeda’s vaccine business unit and co-lead of the company’s COVID-19 response team.

Opinions


Popular News

Latest News